As new litigation looms in the debate over use of copay accumulator programs, a look at potential next moves for payers—and steps drug manufacturers should take to ward off cost-driven non-adherence.
Chris Dowd
Advertisement
Articles by Chris Dowd
Amid shifting healthcare cost strategies, how manufacturers can apply past lessons to best support patients and help boost drug adherence.
Advertisement
Latest Updated Articles
Copay Adjustment Programs: What’s Next for Manufacturers?Published: February 19th 2024 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Ypsomed Announces New U.S.-Based Manufacturing Site in North Carolina
2
AstraZeneca to Announce Deal with Trump Administration: Report
3
Bristol Myers Squibb Enters $1.5 Billion Definitive Agreement Acquiring Orbital Therapeutics
4
Pharmaceutical Executive Daily: Most Favored Nation Order's Evolving Landscape
5
